ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2012
Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Global landscape of vancomycin-resistant enterococci in hematopoietic stem-cell transplantation patients: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- VRE and VSE Bacteremia Outcomes in the Era of Effective VRE Therapy: A Systematic Review and Meta-analysis.Infection control and hospital epidemiology · 2016Pooled it
- Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Blood advances · 2026Trial
- Vancomycin-resistant Enterococcus faecium Bacteremia in a tertiary care hospital: epidemiology, antimicrobial susceptibility, and outcome.BioMed research international · 2014Trial
- Effectiveness of Bath Wipes After Hematopoietic Cell Transplantation: A Randomized Trial.Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology NursesTrial
- Risk Factors and Outcomes of Vancomycin-ResistantOpen forum infectious diseases · 2026Article
- Who is at risk? Clinical features and a predictive model for 30-day mortality in hematologic patients with enterococcal bloodstream infection.Frontiers in cellular and infection microbiology · 2026Article
- Impact of vancomycin resistance on attributable mortality among Enterococcus faecium bloodstream infections: propensity score analysis of a large, multicentre retrospective study.The Journal of antimicrobial chemotherapy · 2025Article
- A 5-Year Epidemiological Study of Monomicrobial Enterococcal Bloodstream Infection in a Population-Based Cohort.Open forum infectious diseases · 2025Article
- Comparison of morbidity and mortality after bloodstream infection with vancomycin-resistant versus -susceptibleEmerging microbes & infections · 2024Article
- Levofloxacin prophylaxis in pediatric oncology and hematopoietic stem cell transplantation: a literature review.Pediatric hematology and oncology · 2024Review
- Characteristics of Enterococcus species bloodstream infections among adults with and without onco-hematological malignancies: Experiences from the national center of Hungary.European journal of microbiology & immunology · 2024Article
- Post-transplantation cyclophosphamide is associated with increased bacterial infections.Bone marrow transplantation · 2024Article
- Incidence, Etiology, Risk Factors, and Outcomes of Bloodstream Infection after a Second Hematopoietic Stem Cell Transplantation.Internal medicine (Tokyo, Japan) · 2023Article
- Global impact of antibacterial resistance in patients with hematologic malignancies and hematopoietic cell transplant recipients.Transplant infectious disease : an official journal of the Transplantation Society · 2023Review
- Antimicrobial Stewardship on Patients with Neutropenia: A Narrative Review Commissioned by Microorganisms.Microorganisms · 2023Review
- Microbiology and Clinical Outcome of Bloodstream Infections in Patients After Hematopoietic Stem Cell Transplantation.Infection and drug resistance · 2023Article
- Mitigation of gastrointestinal graft-Haematologica · 2023Article
- Infectious complications after second allogeneic hematopoietic cell transplant in adult patients with hematological malignancies.Bone marrow transplantation · 2022Article
- Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia.BMC infectious diseases · 2022Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
backgroundEnterococci are an important cause of healthcare-associated infections. We retrospectively analyzed risk factors and outcome of vancomycin-resistant enterococci (VRE) and vancomycin-sensitive enterococci (VSE) infections.
methodsSeven hundred fifty-two patients who received hematopoietic stem cell transplants from 2004 through 2008 at the University of Minnesota were included.
resultsNinety-three patients had enterococcal bloodstream infection (BSI) during the first year after transplant. Vancomycin resistance was observed in 66% and 31% of isolates in adults and children, respectively. Cumulative incidence of VRE and VSE bacteremia was 6.6% (95% confidence interval [CI], 4.8%-8.4%) and 5.7% (95% CI, 4.0%-7.4%), respectively. Colonization with VRE before or after transplant was a risk factor for VRE bacteremia (odds ratio [OR], 3.3 [95% CI, 1.3-8.3] and 7.0 [95% CI, 4.0-14.8], respectively). Delay in engraftment increased the incidence of VRE bacteremia from 4.5% (95% CI, 2.9-6.6) if engrafted before day 21 and to 15% (95% CI, 3.2%-38%) if engrafted between days 36 and 42. In adults, mortality 30 days after infection was 38% for both VRE (95% CI, 25%-54%) and VSE cases (95% CI, 21%-62%). The hazard ratio for all-cause mortality up to 1 year after transplant was 4.2 (95% CI, 3.1-6.9) and 2.7 (95% CI, 1.4-5.1) for patients with VRE and VSE BSIs, respectively, compared to patients without enterococcal BSI. In pediatric patients, mortality 30 days after VRE and VSE bacteremia was 20% (95% CI, 5.4%-59%) and 4.5% (95% CI, .6%-28%), respectively.
conclusionHigh rates of vancomycin resistance and association of enterococcal infections with significant mortality warrant further efforts to optimize prevention and management of these infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.